Page last updated: 2024-12-04

am 251

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

AM 251: an analog of SR141716A; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2125
CHEMBL ID285932
CHEBI ID90724
SCHEMBL ID1040316
MeSH IDM0270611

Synonyms (91)

Synonym
CBIOL_001833
HMS3267K22
HMS3394K15
BRD-K92000912-001-02-7
BSPBIO_001525
BIO1_001097
BIO1_000119
tocris-1117
BIO2_000725
NCGC00025011-01
BIO2_000245
BIO1_000608
IDI1_033995
1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-n-(piperidin-1-yl)-1h-pyrazole-3-carboxamide
n-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1h-pyrazole-3-carboxamide
bdbm21279
MLS001424171
am 251
n-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide
am251 ,
chembl285932 ,
am251, >98% (hplc), solid
MLS000758233
smr000466284
am-251
cpd000466284
NCGC00025011-02
NCGC00025011-03
n-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide
KBIO3_000489
KBIO2_005381
KBIO3_000490
KBIO2_002813
KBIO2_000245
KBIOSS_000245
KBIOGR_000245
NCGC00025011-04
183232-66-8
HMS2052K15
HMS1989M07
chebi:90724 ,
L000964
BML3-F08
HMS1791M07
HMS1361M07
1h-pyrazole-3-carboxamide, 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-n-1-piperidinyl-
FT-0661538
1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-n-piperidin-1-ylpyrazole-3-carboxamide
C20220
BCP9000280
CCG-101124
3i4fa44mai ,
am 251 (pharmaceutical)
unii-3i4fa44mai
S2819
gtpl3317
SCHEMBL1040316
NC00374
1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-n-(1-piperidyl)pyrazole-3-carboxamide
CS-3920
DTXSID7042695
c22h21cl2in4o
1-(2,4-dichloro-phenyl)-5-(4-iodo-phenyl)-4-methyl-1h-pyrazole-3-carboxylic acid piperidin-1-ylamide
BUZAJRPLUGXRAB-UHFFFAOYSA-N
n-(piperidin-1-yl)-5-(4-iodophenyl) -1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-car boxamide
HB2776
AC-32778
HY-15443
AKOS024456393
HMS3649G04
HMS3402M07
EX-A696
SR-01000597360-1
sr-01000597360
HMS3651B15
AS-74465
J-011727
SW197754-2
BCP21728
am 251; am-251
Q4652514
HMS3676I21
SR-01000597360-6
HMS3412I21
BRD-K92000912-001-06-8
A12914
SB19550
HMS3884H18
A880838
BA17338
am-251 is known as a cb1 receptor antagonist.

Research Excerpts

Effects

ExcerptReferenceRelevance
"AM 251, however, has no anxiolytic effect when the time spent in the center of the OF is considered."( Cannabinoid type 1 receptor ligands WIN 55,212-2 and AM 251 alter anxiety-like behaviors of marmoset monkeys in an open-field test.
Barros, M; Cagni, P, 2013
)
1.36

Treatment

ExcerptReferenceRelevance
"Treatment with AM 251 aggravated gastric damage and reversed protective effect of anandamide administration."( Cannabinoids in acute gastric damage and pancreatitis.
Ceranowicz, P; Cieszkowski, J; Dembiński, A; Dembiński, M; Hładki, W; Konturek, PC; Konturek, SJ; Pawlik, WW; Tomaszewska, R; Warzecha, Z, 2006
)
0.67

Toxicity

ExcerptReferenceRelevance
" These toxic effects were attenuated by CB1R knockout or CB1R antagonists."( Genetic or pharmacological depletion of cannabinoid CB1 receptor protects against dopaminergic neurotoxicity induced by methamphetamine in mice.
Dang, DK; Jang, CG; Jeong, JH; Kim, HC; Ledent, C; Mai, AT; Nabeshima, T; Nah, SY; Onaivi, ES; Shin, EJ; Yamamoto, T, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
" Thus, changes in CB1r function - alone and in combination with cocaine - affected stereotyped vigilance-related behaviors in this NHP, further implicating the eCB system in the neurobiological mechanisms of cocaine addiction."( Cannabinoid type-1 receptor ligands, alone or in combination with cocaine, affect vigilance-related behaviors of marmoset monkeys.
Barros, M; Cagni, P; de Jesus, AG; Melo, GC, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
"We determined the effect of a cannabinoid CB1 receptor antagonist (AM-251; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) on food intake, body weight and adipose tissue mass in Western diet-induced obese (DIO) mice using a chronic, interrupted, oral dosing paradigm."( Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice.
Black, SC; Hildebrandt, AL; Kelly-Sullivan, DM, 2003
)
0.32
" Moreover, the CB1 antagonists right-shifted A1 agonist dose-response curves without affecting maximal responses, suggesting competitive mode of antagonist action."( An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
Järvinen, T; Laitinen, JT; Niemi, R; Saario, SM; Savinainen, JR, 2003
)
0.32
" For this purpose, 129/SVE and C57BL/6 male mice were acutely dosed intraperitoneally (i."( Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice.
Fleischer, R; Rocha, BA; Rosko, KM; Shearman, LP; Tong, XS; Wang, J; Xu, S, 2003
)
0.32
" However, combined oral dosing of nalmefene and subthreshold doses of AM251, a cannabinoid CB1 receptor inverse agonist, led to a significant reduction in food intake in both lean and diet-induced obese (DIO) mice."( Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice.
Chen, RZ; Fong, TM; Huang, RR; MacNeil, DJ; Shen, CP, 2004
)
0.32
" Dose-response curve for a beta-adrenergic agonist isoproterenol was constructed in the presence and absence of a CB-1 antagonist AM251 (1 microM)."( Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.
Baik, SK; Gaskari, SA; Lee, SS; Li, Y; Liu, H; Moezi, L, 2005
)
0.33
" The effect of AM 251 of food intake and body weight was examined in daily (1 mg kg(-1)) and 5-day (5 mg kg(-1)) dosing schedules."( AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion.
Chambers, AP; Koopmans, HS; Pittman, QJ; Sharkey, KA, 2006
)
2.13
"05-5pmol) induced anxiolytic-like effects with bell-shaped dose-response curves, the higher doses being ineffective."( Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray.
Aguiar, DC; Guimarães, FS; Moreira, FA, 2007
)
0.34
"05); the dose-response curve was shifted to the left in the obese."( Effects of cannabinoid receptors on skeletal muscle oxidative pathways.
Cameron-Smith, D; Cavuoto, P; Hatzinikolas, G; McAinch, AJ; Wittert, GA, 2007
)
0.34
"CBD injected into the dlPAG produced anxiolytic-like effects in the EPM with a bell-shaped dose-response curve."( Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats.
Campos, AC; Guimarães, FS, 2008
)
0.35
" Our results indicate clearly a dose-response blockade of extinction induced by AM251 injected into the striatum but a facilitation of extinction when administered into the hippocampus."( Impairment of endocannabinoids activity in the dorsolateral striatum delays extinction of behavior in a procedural memory task in rats.
Méndez-Díaz, M; Montes-Rodriguez, CJ; Prospéro-García, O; Rueda-Orozco, PE; Soria-Gomez, E, 2008
)
0.35
", the compound consistently increased anxiety parameters in all of the three different anxiety tests applied, while a lower dosage of 1mg/kg had no such effect."( Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.
Hasenöhrl, RU; Ledent, C; Molleman, A; Thiemann, G; Watt, CA, 2009
)
0.35
"Streptozotocin-induced diabetic mice were treated with N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,3-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251), a selective CB1-receptor antagonist, at the dosage of 1 mg x kg(-1) x day(-1) via intraperitoneal injection for 14 weeks."( Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy.
Barutta, F; Corbelli, A; Di Marzo, V; Gambino, R; Gruden, G; Mastrocola, R; Perin, PC; Pinach, S; Rastaldi, MP, 2010
)
0.36
"05-10 μg/mouse) produced antidepressant-like effect dose-dependently, whereas influenced the MBB in a biphasic manner (produced a U-shaped dose-response curve)."( Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice.
Jain, NS; Manna, SS; Umathe, SN, 2011
)
0.37
" Starting from a high-throughput screening lead, we prepared a series of BRS-3 agonists with improved potency and pharmacokinetic properties, of which compound 8a caused mechanism-based, dose-dependent food intake reduction and body weight loss after oral dosing in diet-induced obese mice."( Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chirality.
Ball, RG; Chang, L; Chioda, M; Chobanian, HR; Dragovic, J; Gao, YD; Gong, X; Guan, XM; Guo, Y; Hornak, V; Jones, C; Kan, Y; Kelly, TM; Lanza, TJ; Lin, LS; Liu, P; Lyons, K; Marsh, DJ; Metzger, JM; Miller, R; Nargund, RP; Ning, JG; Palyha, O; Pang, J; Ramsay, K; Reitman, ML; Schafer, WA; Strack, AM; Tsou, N; Wang, SP; Welch, CJ; Wyvratt, MJ, 2011
)
0.37
" Lethality was increased by AM251 with the higher dosage of PO, but no lethality was noted with either dosage of CPO, with or without AM251."( The cannabinoid receptor antagonist AM251 increases paraoxon and chlorpyrifos oxon toxicity in rats.
Liu, J; Pope, C, 2015
)
0.42
"3, 1, and 3 mg/kg) enhanced cumulative food intake during the first 12 h with a dome-shaped dose-response relationship in freely fed rats, with the most effective dose being 1 mg/kg."( Differential modulation of endogenous cannabinoid CB1 and CB2 receptors in spontaneous and splice variants of ghrelin-induced food intake in conscious rats.
Chen, CY; Chi, CW; Li, CP; Ting, CH, 2015
)
0.42
" To constitute morphine tolerance, we used a 3 day cumulative dosing regimen."( Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists.
Altun, A; Bagcivan, I; Durmus, N; Gursoy, S; Ozdemir, E; Yildirim, K, 2015
)
0.42
"Intra-DMH anandamide treatment yielded a U-shaped dose-response curve with no effect of the lowest (0."( Opposing roles of dorsomedial hypothalamic CB1 and TRPV1 receptors in anandamide signaling during the panic-like response elicited in mice by Brazilian rainbow Boidae snakes.
Coimbra, NC; Dos Anjos-Garcia, T, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
CB1 receptor antagonistAn antagonist that binds to and deactivates type 1 cannabinoid receptors.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
pyrazoles
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
amidopiperidine
carbohydrazideA hydrazide consisting of hydrazine carrying one or more carboacyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency22.38720.044717.8581100.0000AID485341
TDP1 proteinHomo sapiens (human)Potency31.67680.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1460
regulator of G-protein signaling 4Homo sapiens (human)Potency29.93490.531815.435837.6858AID504845
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency3.98110.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency7.94330.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency1.99530.00636.904339.8107AID883
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.00000.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency3.98110.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency10.00000.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency1.99530.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)Ki2.29000.00031.21858.9270AID482751
Cannabinoid receptor 1Rattus norvegicus (Norway rat)Ki0.00290.00020.566510.0000AID49497; AID49498
Cannabinoid receptor 1Homo sapiens (human)IC50 (µMol)0.08920.00010.275310.0000AID318853; AID318854; AID318855; AID318856; AID318857; AID318858; AID318864
Cannabinoid receptor 1Homo sapiens (human)Ki0.01670.00010.50779.6000AID1798064; AID308101; AID317007; AID342487; AID436963; AID482750; AID545479
Cannabinoid receptor 2 Homo sapiens (human)Ki0.37030.00000.415610.0000AID1798064; AID317008; AID342488; AID436964; AID482751; AID545480; AID569313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cannabinoid receptor 1Homo sapiens (human)EC50 (µMol)0.06510.00010.12752.2400AID1181921; AID1186769
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
positive regulation of acute inflammatory response to antigenic stimulusCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
spermatogenesisCannabinoid receptor 1Homo sapiens (human)
axonal fasciculationCannabinoid receptor 1Homo sapiens (human)
response to nutrientCannabinoid receptor 1Homo sapiens (human)
memoryCannabinoid receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentCannabinoid receptor 1Homo sapiens (human)
negative regulation of serotonin secretionCannabinoid receptor 1Homo sapiens (human)
positive regulation of fever generationCannabinoid receptor 1Homo sapiens (human)
negative regulation of fatty acid beta-oxidationCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, GABAergicCannabinoid receptor 1Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 1Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 1Homo sapiens (human)
negative regulation of dopamine secretionCannabinoid receptor 1Homo sapiens (human)
response to nicotineCannabinoid receptor 1Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 1Homo sapiens (human)
response to cocaineCannabinoid receptor 1Homo sapiens (human)
glucose homeostasisCannabinoid receptor 1Homo sapiens (human)
positive regulation of apoptotic processCannabinoid receptor 1Homo sapiens (human)
response to ethanolCannabinoid receptor 1Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 1Homo sapiens (human)
negative regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
positive regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
regulation of insulin secretionCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCannabinoid receptor 1Homo sapiens (human)
maternal process involved in female pregnancyCannabinoid receptor 1Homo sapiens (human)
regulation of feeding behaviorCannabinoid receptor 1Homo sapiens (human)
regulation of penile erectionCannabinoid receptor 1Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoidCannabinoid receptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationCannabinoid receptor 1Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 1Homo sapiens (human)
response to amphetamineCannabinoid receptor 2 Homo sapiens (human)
inflammatory responseCannabinoid receptor 2 Homo sapiens (human)
immune responseCannabinoid receptor 2 Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 2 Homo sapiens (human)
leukocyte chemotaxisCannabinoid receptor 2 Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicCannabinoid receptor 2 Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 2 Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 2 Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 2 Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 2 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
cannabinoid receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 1Homo sapiens (human)
identical protein bindingCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 2 Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
mitochondrial outer membraneCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
actin cytoskeletonCannabinoid receptor 1Homo sapiens (human)
growth coneCannabinoid receptor 1Homo sapiens (human)
presynaptic membraneCannabinoid receptor 1Homo sapiens (human)
membrane raftCannabinoid receptor 1Homo sapiens (human)
glutamatergic synapseCannabinoid receptor 1Homo sapiens (human)
GABA-ergic synapseCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
cytoplasmCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
dendriteCannabinoid receptor 2 Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneCannabinoid receptor 2 Homo sapiens (human)
perikaryonCannabinoid receptor 2 Homo sapiens (human)
endoplasmic reticulumCannabinoid receptor 2 Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
cytoplasmCannabinoid receptor 2 Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (76)

Assay IDTitleYearJournalArticle
AID304329Inhibition of rat brain FAAH assessed by measuring [14C]anandamide hydrolysis at 50 uM after 30 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain.
AID375664Activity at CB2 receptor in human basophil assessed as reduction of anti-IgE-FITC conjugated antibody-stimulated CD203c expression after 30 mins by flow cytometric analysis in presence of 100 nM AM2512009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists.
AID49860Binding affinity against Cannabinoid receptor 2 in mouse spleen1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
AID1181921Inverse agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Galpha i2 assessed as Galpha GTPase activity using [gamma-33P]GTP by scintillation counting in presence of CP559402014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB₂R selective benzimidazoles reveal unexpected intrinsic properties.
AID1724606Antagonist activity at cannabinoid receptor in ICR mouse vas deferens assessed as reduction of WIN55212-2-induced inhibition of electrically evoked contraction at 1 uM incubated for 10 mins prior to WIN55212-2 addition2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
New cannabinoid receptor antagonists as pharmacological tool.
AID704594Antiobesity activity in diet-induced obese wild type C57 mouse assessed as weight loss at 3 mg/kg, po administered QD 60 mins prior to dark cycle onset relative to control2011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chirality.
AID1601881Agonist activity at cannabinoid receptor in ICR mouse vas deferens assessed as inhibition of electrically induced contractions at 3 x 10'-7 M after 10 mins in presence of CB1 antagonist AM251 relative to control2019European journal of medicinal chemistry, Mar-15, Volume: 166Indazolylketones as new multitarget cannabinoid drugs.
AID318859Ratio of IC50 for human CB1R F200L mutant to IC50 for human wild type CB1R2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID545481Selectivity index ratio of Ki for recombinant human CB2 to Ki for recombinant human CB1 receptor2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
AID692464Toxicity in diet-induced obese C57BL6 mouse assessed as adverse effect in skin at 10 mg/kg, po measured within 5 to 10 days2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
AID318853Displacement of [3H]CP-55940 from human wild type CB1R expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID308101Binding affinity to human CB1 receptor2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.
AID1601884Agonist activity at cannabinoid receptor in ICR mouse vas deferens assessed as inhibition of electrically induced contractions at 8.1 x 10'-6 M after 10 mins in presence of CB1 antagonist AM251 relative to control2019European journal of medicinal chemistry, Mar-15, Volume: 166Indazolylketones as new multitarget cannabinoid drugs.
AID318854Displacement of [3H]CP-55940 from human CB1R F200L mutant expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID436965Selectivity index, ratio of Ki for human recombinant CB2 receptor to Ki for human recombinant CB1 receptor2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity
AID1562903Displacement of [3H]JWH-018 from CB1R/CB2R in Wistar rat brain membranes after 60 mins by liquid scintillation analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID304330Antagonist activity at human recombinant TRPV1 receptor expressed in HEK293 cells assessed as inhibition of capsaicin-induced intracellular calcium elevation at 10 uM2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain.
AID49497Binding affinity was determined by using a competition assay with [125 I]- AM251 against rat cannabinoid receptor 12003Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4
Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.
AID1601883Agonist activity at cannabinoid receptor in ICR mouse vas deferens assessed as inhibition of electrically induced contractions at 2.7 x 10'-6 M after 10 mins in presence of CB1 antagonist AM251 relative to control2019European journal of medicinal chemistry, Mar-15, Volume: 166Indazolylketones as new multitarget cannabinoid drugs.
AID49498Binding affinity against Cannabinoid receptor 1 in rat forebrain1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
AID1245644Antagonist activity at CB1R in rat cerebellar membranes assessed as inhibition of HU210-induced response at 1 uM by [35S]GTPgammaS binding assay2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Revisiting 1,3,4-Oxadiazol-2-ones: Utilization in the Development of ABHD6 Inhibitors.
AID19935Partition coefficient (logD7.4)2003Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4
Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.
AID1601885Agonist activity at cannabinoid receptor in ICR mouse vas deferens assessed as inhibition of electrically induced contractions at 1.82 x 10'-5 M after 10 mins in presence of CB1 antagonist AM251 relative to control2019European journal of medicinal chemistry, Mar-15, Volume: 166Indazolylketones as new multitarget cannabinoid drugs.
AID1724607Inverse agonist activity at cannabinoid receptor in ICR mouse vas deferens assessed as inhibition of electrically evoked contractile response2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
New cannabinoid receptor antagonists as pharmacological tool.
AID660306Antagonist activity at CB1 receptor in ICR mouse vas deferens assessed as inhibition of ACEA-stimulated electrically-induced muscle contraction at 10'-6 M2011ACS medicinal chemistry letters, Nov-10, Volume: 2, Issue:11
Discovery of Potent Dual PPARα Agonists/CB1 Ligands.
AID318864Displacement of [3H]SR-141716 from human wild type CB1R expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID545480Displacement of [3H]CP-55,940 from recombinant human CB2 receptor transfected in HEK cells2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
AID1193640Antagonist activity at rat cerebellar membrane cannabinoid CB1 receptor assessed as HU210-evoked [35S]GTPgammaS binding response at 1 uM relative to control2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Loratadine analogues as MAGL inhibitors.
AID436963Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in HEK cells2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity
AID447181Antidiabetic activity in high-fat diet fed mouse C57BL/6 assessed as reduction of body weight gain at 0.014% w/w formulated in diet after 7 weeks2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.
AID318863Ratio of IC50 for human CB1R F170L mutant to IC50 for human wild type CB1R2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID1186770Inverse agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Gbeta1gamma2 and RSG4 assessed as degradation of [gamma-33P]GTP at 30 uM after 20 mins by steady-state GTPase assay relative to control2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure.
AID318857Displacement of [3H]SR-141716 from human CBR1 S383A mutant expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID1186769Inverse agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Gbeta1gamma2 and RSG4 assessed as degradation of [gamma-33P]GTP after 20 mins by steady-state GTPase assay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure.
AID317009Ratio of Ki for human recombinant CB1 receptor to human recombinant CB2 receptor2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.
AID230761Ratio of the binding affinities against rat CB1 to that of mouse CB2; activity value is 1:3061999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
AID482751Binding affinity to cannabinoid CB2 receptor2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Emerging targets in osteoporosis disease modification.
AID1562904Displacement of [3H]JWH-018 from CB1R in Wistar rat brain membranes at 10 uM after 60 mins by liquid scintillation analysis relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID436964Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in HEK cells2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity
AID318855Displacement of [3H]CP-55940 from human CB1R W279A mutant expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID1601880Agonist activity at cannabinoid receptor in ICR mouse vas deferens assessed as inhibition of electrically induced contractions at 10'-7 M after 10 mins in presence of CB1 antagonist AM251 relative to control2019European journal of medicinal chemistry, Mar-15, Volume: 166Indazolylketones as new multitarget cannabinoid drugs.
AID318861Ratio of IC50 for human CB1R K192L mutant to IC50 for human wild type CB1R2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID318858Displacement of [3H]CP-55940 from human CB1R F170L mutant expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID80453Dissociation constant [100(nM)] in myenteric plexus-longitudinal muscle of guinea pig small intestine using the cannabinoid receptor agonist.1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
AID49669Inhibition of [3H]CP-55940 binding to cannabinoid receptor 1 in rat brain membranes.2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
AID342487Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in HEK cells2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Novel sterically hindered cannabinoid CB1 receptor ligands.
AID317007Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in HEK cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.
AID342488Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in HEK cells2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Novel sterically hindered cannabinoid CB1 receptor ligands.
AID569313Displacement of [3H]CP 55940 from human CB2 receptor in cell free system2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
AID21880Distribution coefficient was determined2003Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4
Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.
AID1601882Agonist activity at cannabinoid receptor in ICR mouse vas deferens assessed as inhibition of electrically induced contractions at 9 x 10'-7 M after 10 mins in presence of CB1 antagonist AM251 relative to control2019European journal of medicinal chemistry, Mar-15, Volume: 166Indazolylketones as new multitarget cannabinoid drugs.
AID388012Agonist activity at human PPARalpha expressed in human MCF7 cells coexpressing TIF2 by luciferase reporter gene assay2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents.
AID545479Displacement of [3H]CP-55,940 from recombinant human CB1 receptor transfected in HEK cells2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
AID692465Toxicity in diet-induced obese C57BL6 mouse assessed as adverse effect in eye at 10 mg/kg, po measured within 5 to 10 days2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
AID482750Binding affinity to cannabinoid CB1 receptor2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Emerging targets in osteoporosis disease modification.
AID1181920Antagonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Galpha i2 assessed as Galpha GTPase activity using [gamma-33P]GTP at 100 uM by scintillation counting in presence of 30 nM CP55940 (Rvb = 0 +/- 3%)2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB₂R selective benzimidazoles reveal unexpected intrinsic properties.
AID1181919Agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Galpha i2 assessed as Galpha GTPase activity using [gamma-33P]GTP at 100 uM by scintillation counting (Rvb = 0 +/- 3%)2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB₂R selective benzimidazoles reveal unexpected intrinsic properties.
AID138508Dissociation constant [31.6(nM)] in mouse isolated vas deferens using the cannabinoid receptor agonist.1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
AID1696824Inverse agonist activity at human CB1 receptor expressed in CHO cell membrane assessed as reduction in GTPgammaS binding at 10 uM by [35S]GTP-gammaS binding assay2020Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22
7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
AID318856Displacement of [3H]CP-55940 from human CB1R K192L mutant expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID318860Ratio of IC50 for human CB1R W279A mutant to IC50 for human wild type CB1R2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID317008Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in HEK cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.
AID318862Ratio of IC50 for human CB1R S383A mutant to IC50 for human wild type CB1R2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1345070Human GPR55 (GPR18, GPR55 and GPR119)2010British journal of pharmacology, Jun, Volume: 160, Issue:3
GPR55 ligands promote receptor coupling to multiple signalling pathways.
AID1346814Human GPR18 (GPR18, GPR55 and GPR119)2012British journal of pharmacology, Apr, Volume: 165, Issue:8
Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells.
AID1345070Human GPR55 (GPR18, GPR55 and GPR119)2009The Journal of biological chemistry, Oct-23, Volume: 284, Issue:43
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
AID1345070Human GPR55 (GPR18, GPR55 and GPR119)2007British journal of pharmacology, Dec, Volume: 152, Issue:7
The orphan receptor GPR55 is a novel cannabinoid receptor.
AID1346753Rat CB1 receptor (Cannabinoid receptors)1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
AID1798064CB Receptor Binding Assay from Article 10.1021/jm070566z: \\Synthesis, Cannabinoid Receptor Affinity, and Molecular Modeling Studies of Substituted 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.\\2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (937)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (0.53)18.2507
2000's347 (37.03)29.6817
2010's536 (57.20)24.3611
2020's49 (5.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.82 (24.57)
Research Supply Index6.86 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.11%)5.53%
Reviews7 (0.74%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other940 (99.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]